drug

Artemisinin

MeSH C031327
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DIETARY_SUPPLEMENT
Pre-approval / investigational in the US
Developed by Beijing HuiLongGuan Hospital
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DIETARY_SUPPLEMENT

Indications

Trials

2
Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia
NCT01391403Phase 3Completed
Artemisinin to Reduce The Symptoms of Schizophrenia
NCT00753506—Completed

KOLs & investigators

2
Faith B Dickerson, PhD, MPHKOL score 5
Lian Y Cao, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Beijing HuiLongGuan Hospital
company
trial
Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia
PHASE3
trial
Artemisinin to Reduce The Symptoms of Schizophrenia
NA
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Faith B Dickerson, PhD, MPH
KOL score 5
person
Lian Y Cao, MD
KOL score —
person